Several randomised controlled trials have demonstrated the benefit and safety of low dose colchicine (traditionally used for gout treatment) to prevent stroke, hear attack and death in survivors of heart attacks. However, it is not known if this treatment will be safe and effective in survivors of stroke. CONVINCE aims to investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care compared with usual care alone to prevent non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, hospitalization for unstable angina and vascular death after ischaemic stroke or transient ischaemic attack (TIA) not caused by cardiac embolism or other defined causes unrelated to atherosclerosis.